anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

216,661-216,720 of 319,975

filter-aware
06
This is a character bio slide for a film or series pitch.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Call to Adventure1 hit
07
The slide presents a character archetype, likely for a film or creative project pitch.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Call to Adventure1 hit
08
Slide describes a fictional character and the actress portraying her.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Call to Adventure1 hit
09
The slide introduces a character named Mr. Endo, played by Ken'ichi Endo, describing his role as the owner of DoggieMart.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Call to Adventure1 hit
10
The slide presents character bios for a film or project, featuring headshots and scene stills.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Call to Adventure1 hit
11
The slide is split into two distinct sections: a character bio for Jared (played by Adam Hagenbuch) and a visual collage of celebrity animals.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Call to Adventure1 hit
12
Uses paw print icons as bullet points.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Need1 hit
13
The slide uses a comparative approach to validate the commercial viability of specific tropes.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Need1 hit
14
AKT Pictures | Other Presentation Deck | 17 slidesAKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Need1 hit
15
AKT Pictures | Other Presentation Deck | 17 slidesAKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Satisfaction1 hit
16
The timeline uses a diagonal layout with numbered steps.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Satisfaction1 hit
17
The slide features the project title 'when I was a human' and a stylized graphic of a person and a dog shadow.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Action1 hit
01
Slide 1
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
02
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
03
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
04
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
05
The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progress.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
06
The slide uses a Gantt-style chart to map drug development stages across different indications.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
07
The slide lists names, titles, and previous company affiliations for both the Board and Management Team.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
08
The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide uses a problem-solution framework to justify the engineering approach for each therapeutic program.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
11
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
12
Uses a vertical process flow diagram to represent development stage gates.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
13
Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
14
The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
15
The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
16
The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
22
The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
25
The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
26
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
29
Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
30
Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
31
The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream effects.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
32
The slide uses a process flow diagram to explain the therapeutic mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
33
Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
34
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
37
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
01
Slide 1
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
02
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
03
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
04
The slide highlights significant growth in revenue and net income metrics year-over-year.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
05
Includes a blue box highlight around the Q3'23 column.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
06
Includes both GAAP and non-GAAP projections, plus specific product revenue breakdowns.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
07
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
08
The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
09
Includes a disclaimer regarding the forward-looking nature of the expectations.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
10
The chart tracks TRx (Total Prescriptions) over 101 weeks.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
11
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit